MGNX - Here's Why MacroGenics Jumped 156.6% in the First Half of 2020
Shares of MacroGenics (NASDAQ: MGNX) soared over 156% in the first six months of the year, according to data provided by S&P Global Market Intelligence. For comparison, the S&P 500 limped through the first half of 2020 with a 4% decline.
The biopharma stock jumped after the company announced progress in the commercialization efforts of margetuximab. MacroGenics expects the U.S. Food and Drug Administration (FDA) to make a decision on a Biologics License Application (BLA) in HER2 positive breast cancer treatment by December 18.
Can the small-cap stock keep its gains ahead of the decision date?